HMGN2P16

Across TCGA pan-cancer cohorts, HMGN2P16 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated HMGN2P16 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher HMGN2P16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated HMGN2P16 expression acts as an unfavorable survival marker, although some lineages such as BRCA show a favorable association.

MESO, LIHC, and READ are the cancer types where HMGN2P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.064	0.576	<.001	153	view →
LIHC	OS	Tertile	All	0.059	0.775	<.001	54	view →
READ	OS	Tertile	II,III,IV	0.535	0.927	.001	42	view →
ACC	DFS	Tertile	All	0.137	0.771	<.001	39	view →
THCA	DFS	Tertile	II,III,IV	0.778	0.918	.005	33	view →
CHOL	OS	Tertile	All	0.089	0.673	.018	18	view →
CESC	DFS	Tertile	IV	0.147	0.545	.008	18	view →
PAAD	OS	Tertile	II,III,IV	0.266	0.566	.008	18	view →
BLCA	OS	Tertile	IV	0.289	0.619	.004	15	view →
BRCA	DFS	Tertile	All	0.990	0.946	.043	6	view →
KIRC	OS	Tertile	All	0.533	0.650	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

HMGN2P16–MESO (OS)

Open the MESO breakdown →